{"id":"W3016549455","doi":"10.1158/1078-0432.ccr-19-3979","title":"FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Canada","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Endometrial cancer; Internal medicine; Oncology; Expanded access; Clinical trial; Cancer; Thyroid cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009053146,0.0007889076,0.0006155915,0.002233089,0.0007122342,0.003018759,0.0009796848,0.002810654,0.01027263],"category_scores_gemma":[0.007719294,0.0003008919,0.00117874,0.001639242,0.0005465759,0.001073069,0.0005619836,0.002092072,0.005362266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002309805,"about_ca_system_score_gemma":0.008665661,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002709087,"about_ca_topic_score_gemma":0.00677867,"domain_scores_codex":[0.9957976,0.001335322,0.0003414634,0.0003727166,0.001869195,0.0002838219],"domain_scores_gemma":[0.9948044,0.0008584275,0.0006748267,0.0001575161,0.003110306,0.0003945465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004708734,0.0001397796,0.0007279863,0.002845098,0.0001246361,0.0002901593,0.0001002891,0.0002268341,0.003785556,0.007062028,0.6789628,0.305264],"study_design_scores_gemma":[0.0001978525,0.0003804958,0.001823376,0.0006606734,0.000103803,0.0002371636,0.00002359677,0.00007833724,0.0009472951,0.0003926594,0.9951419,0.00001296361],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01502668,0.4126293,0.00877921,0.1219815,0.0319692,0.007087062,0.01311842,0.001181841,0.3882268],"genre_scores_gemma":[0.09234675,0.3617256,0.0279776,0.1122605,0.02335254,0.004575883,0.0196835,0.0005514915,0.3575262],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01027263,"threshold_uncertainty_score":0.04787815,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4459423475339773,"score_gpt":0.5660444547712383,"score_spread":0.1201021072372611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}